- Home
- DV vs DYN Comparison
DV vs DYN Comparison
Compare DV & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DV
- DYN
- Stock Information
- Founded
- DV 2008
- DYN 1984
- Country
- DV United States
- DYN United States
- Employees
- DV N/A
- DYN N/A
- Industry
- DV Computer Software: Prepackaged Software
- DYN Medicinal Chemicals and Botanical Products
- Sector
- DV Technology
- DYN Health Care
- Exchange
- DV Nasdaq
- DYN Nasdaq
- Market Cap
- DV 3.0B
- DYN 3.4B
- IPO Year
- DV 2021
- DYN 2020
- Fundamental
- Price
- DV $19.13
- DYN $28.39
- Analyst Decision
- DV Buy
- DYN Strong Buy
- Analyst Count
- DV 18
- DYN 9
- Target Price
- DV $25.53
- DYN $52.44
- AVG Volume (30 Days)
- DV 2.7M
- DYN 1.0M
- Earning Date
- DV 11-06-2024
- DYN 11-12-2024
- Dividend Yield
- DV N/A
- DYN N/A
- EPS Growth
- DV 18.39
- DYN N/A
- EPS
- DV 0.38
- DYN N/A
- Revenue
- DV $638,459,000.00
- DYN N/A
- Revenue This Year
- DV $19.75
- DYN N/A
- Revenue Next Year
- DV $14.34
- DYN N/A
- P/E Ratio
- DV $50.57
- DYN N/A
- Revenue Growth
- DV 19.57
- DYN N/A
- 52 Week Low
- DV $16.12
- DYN $9.82
- 52 Week High
- DV $43.00
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- DV 56.70
- DYN 42.04
- Support Level
- DV $16.79
- DYN $27.99
- Resistance Level
- DV $20.62
- DYN $35.68
- Average True Range (ATR)
- DV 0.79
- DYN 2.09
- MACD
- DV 0.19
- DYN 0.23
- Stochastic Oscillator
- DV 61.10
- DYN 9.12
About DV DoubleVerify Holdings Inc.
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. The DV Authentic Ad ensures that a digital ad was delivered in a brand-safe setting, completely viewable, by a real individual, and in the expected geography, is one of its solutions. It generates revenues from its advertisement customers by charging a Measured Transaction Fee on the volume of Media Transactions Measured on the software platform.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.